Deep Learning Model Applied to Digital Pathology Slides Could Predict the Risk of Relapse in Invasive Breast Cancer
Development of novel model for prediction of distant relapse in patients with early breast cancer
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
Safety and Antitumour Activity of a First-in-Class, Oral, Selective CDK7 Inhibitor
Findings from a first-in-human, modular study with samuraciclib (CT7001)
Trastuzumab Deruxtecan Demonstrates Robust and Durable Activity in Previously Treated Metastatic NSCLC with HER2 mutations
The results from the DESTINY-Lung01 study
The Use of Geriatric Assessment Tools to Tailor the Treatment in Elderly Patients with Locally Advanced Head and Neck Cancer
The results of the ELDERLY study
Antitumour Activity of Ceralasertib in ARID1A-Deficient Solid Tumours
Interim results from a phase II study with and ATR inhibitor ceralasertib
Significant PFS Improvement at 3 Years with Neoadjuvant dd-MVAC Regimen in Patients with MIBC
Results of the GETUG/AFU VESPER V05 study
Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer
The results from a prospective, phase III clinical study of extended treatment with 5 years of letrozole compared to 2 to 3 years of letrozole
Bintrafusp Alfa Shows the Long-Term Efficacy and Safety in Patients with HPV–Associated Malignancies
The results from the studies conducted in patients with human papillomavirus associated malignancies
Intermittent Relacorilant Combined with Nab-paclitaxel Improves PFS in Recurrent Platinum-Resistant Ovarian Cancer
Findings from a randomised, open-label, phase II study
FDA Grants Accelerated Approval to Mobocertinib for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
FDA also approved the Oncomine Dx Target Test as a companion diagnostic device
Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily Pretreated B-Cell Non-Hodgkin Lymphoma
Findings from a first-in-human phase I/II study that evaluated subcutaneous, highly selective and potent bispecific antibody targeting CD3 and CD20
Long-Term, Poorly Controlled Diabetes May Impair Efficacy of Immune Checkpoint Inhibitors
Findings from a large, multicentre, retrospective cohort of patients with advanced cancer